Browse Articles

Filter By:

  • Integrins are involved in joint tissue development and homeostasis, and perturbations in the availability of integrin ligands or in downstream integrin signalling are linked to the pathogenesis of osteoarthritis (OA). This Review discusses current evidence and future perspectives for therapeutically targeting integrins in OA.

    • Michael Z. Miao
    • Janice S. Lee
    • Richard F. Loeser
    Review Article
  • Treatment with the endogenous metabolite itaconate induced phenotypic and metabolic changes in fibroblast-like synoviocytes and reduced the severity of arthritis in an animal model.

    • Sarah Onuora
    Research Highlight
  • Sjögren syndrome is a chronic autoimmune disease affecting exocrine glands, causing dryness and systemic symptoms. Treatment has been primarily symptomatic, but advances in our understanding of its pathophysiology offer promise for targeted therapies, aiming for personalized care and improved outcomes.

    • Chiara Baldini
    • Giovanni Fulvio
    • Francesco Ferro
    Review Article
  • New findings identify HSP60 and other synovial stromal-derived autoantigens as targets for pathogenic autoantibodies, exacerbating arthritis and serving as potential biomarkers.

    • Jessica McHugh
    Research Highlight
  • Type 2 innate lymphoid cells protect against kidney inflammation in lupus nephritis, and enhancing their adhesion via integrin α4β7 upregulation, particularly through IL-33 treatment, could be a promising therapeutic approach.

    • Jessica McHugh
    Research Highlight
  • FNIP1- and TFEB-dependent secretion of IGF2 by dystrophic muscles contributes to muscle–bone crosstalk.

    • Maria Papatriantafyllou
    Research Highlight
  • This Review outlines the role of platelets in Kawasaki disease and the immune-effector role of platelets in amplifying inflammation related to Kawasaki disease vasculitis and highlights therapeutic strategies that target platelets or platelet-derived molecules.

    • Magali Noval Rivas
    • Begüm Kocatürk
    • Moshe Arditi
    Review Article
  • The bispecific T cell engager (BiTE) blinatumomab showed promising clinical efficacy in a pilot study of six patients with multidrug-resistant rheumatoid arthritis.

    • Jessica McHugh
    Research Highlight
  • In this Review, the authors provide an overview of the immunological, clinical and pathophysiological features of anti-citrullinated protein antibodies in rheumatoid arthritis, highlighting the latest findings regarding the complex contribution of anti-citrullinated protein antibodies to the disease.

    • Bruno Raposo
    • Lars Klareskog
    • Caroline Grönwall
    Review Article
  • A wearable smart device that uses reconfigurable electronics and conductive polymer-based microneedles was able to monitor inflammation and provide transdermal drug delivery and electrical stimulation in a rat model of arthritis.

    • Maria Papatriantafyllou
    Research Highlight
  • Researchers have introduced the term ‘MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic’ (MIP-C) to describe cases of MDA5 autoimmunity that surged during the COVID-19 pandemic.

    • Jessica McHugh
    Research Highlight
  • As the pace of genetic discovery has accelerated, so too has the need for clinicians and researchers to acknowledge and understand the impact of language in scientific publications. The use of inaccurate language contributes to systemic bias and eugenic ideologies that remain pervasive in biomedical science, including in rheumatology.

    • Paula S. Ramos
    • S. Sam Lim
    Comment
  • Guidelines for the management of psoriatic arthritis (PsA) need to undergo revision to take on board new evidence, particularly in relation to therapeutics. In March 2024, EULAR published updated recommendations for the pharmacological treatment of PsA, and an expert group published consensus statements intended to complement existing guidelines.

    • Ennio Lubrano
    • Fabio Massimo Perrotta
    News & Views
  • Understanding the molecular endotypes that influence clinical phenotypes is a critical step for the stratification of patients with osteoarthritis (OA) into therapeutic subtypes that can help the development of targeted disease-modifying OA drugs (DMOADs) to provide genuine, long-term clinical benefit.

    • Ali Mobasheri
    • Richard Loeser
    Comment